A Study Of MCG In Cardiac Amyloidosis

Not yet recruiting

• Conditions: Amyloidosis

• Registration Number: NCT07218705
• Lead Sponsor: Mayo Clinic

Brief Summary

The primary objective of this observational study is to evaluate the utility of magnetocardiography (MCG) in diagnosing and monitoring disease progression in patients with amyloidosis, and to assess its effectiveness in comparison to other modalities, such as ECG.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-10
• Study First Submitted: 2025-10-16
• Study First Submitted QC: 2025-10-16
• Last Update Submitted: 2025-10-16
• Study First Posted: 2025-10-20
• Last Update Posted: 2025-10-20
• Study Start: 2025-11-01
• Primary Completion: 2027-11
• Study Completion: 2027-11-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Receiver Operating Characteristic (ROC) curve	Baseline, 6 Months, 12 Months, 18 Months	Receiver Operating Characteristic (ROC) curve is used to compare true positive rate vs false positive rate. This will be used to determine the sensitivity, specificity, and overall effectiveness of MCG.
Area Under the Curve (AUC) Magnetocardiography	Baseline, 6 Months, 12 Months, 18 Months	Area Under the Curve (AUC) will be measured by mg\*h/L.
Area Under the Curve (AUC) Electrocardiogram	Baseline, 6 Months, 12 Months, 18 Months	Area Under the Curve (AUC) will be measured by mg\*h/L.

Trial Locations

Locations (1)

Mayo Clinic in Rochester; 🇺🇸 Rochester, Minnesota, United States